Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

Oncotarget
M E CazzanigaValter Torri On Behalf Of The Eva Study Group

Abstract

The present analysis focuses on real-world data of Everolimus-Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and {greater than or equal to} 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel-Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged {greater than or equal to} 65 years, of whom 87 were {greater than or equal to} 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged {greater than or equal to} 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (>7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomat...Continue Reading

References

Jul 1, 2008·Journal of Oncology Practice·Michele BascheJohn F Steiner
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Mar 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H S RugoH A Burris
Nov 3, 2016·The New England Journal of Medicine·Gabriel N HortobagyiJoyce O'Shaughnessy
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Dec 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rachel A FreedmanArti Hurria
Apr 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H S RugoH A Burris

❮ Previous
Next ❯

Citations

Feb 6, 2019·Biomolecules·Nadia R ZgajnarMario D Galigniana

❮ Previous
Next ❯

Software Mentioned

BALLET
BOLERO
EXE
EVE

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.